

## GENDER AND PERCEPTION OF DYSPNEA

## THE ROLE OF THE VARIATION IN THE FORCED EXPIRATORY VOLUME IN ONE SECOND

CARLOS A. NIGRO, MARIA EUGENIA ALAIS, EDGARDO E. RHODIUS

*Laboratorio Pulmonar, Hospital Alemán, Buenos Aires, Argentina*

**Abstract** During bronchoconstriction women perceive more breathlessness than men. The aims of study were 1) to evaluate if quality of dyspnea in bronchoconstriction was different in women and men 2) to assess if gender difference in the perception of dyspnea could be related to the level of bronchoconstriction. 457 subjects (257 women) inhaled methacholine to a 20% decrease in FEV<sub>1</sub>, or 32 mg/ml. Dyspnea was evaluated using the modified Borg scale and a list of expressions of dyspnea. Borg scores were recorded immediately before the challenge test baseline and at the maximum FEV<sub>1</sub> decrease. The prevalence of descriptors of dyspnea reported by women and men was similar. Dyspnea was related to the level of FEV<sub>1</sub> ( $\Delta$ FEV<sub>1</sub>: OR 1.05, 95%CI 1.01-1.09, p 0.0095), females (OR 2.90, 95%CI 1.33-6.33, p 0.0072), younger subjects (OR 0.93, 95%CI 0.89-0.97, p 0.0013) and body mass index (BMI) (OR 1.11, 95%CI 1.01-1.23, p 0.023). As the FEV<sub>1</sub> fell less than 20% from baseline, only the  $\Delta$ FEV<sub>1</sub> was significantly associated with dyspnea ( $\Delta$ FEV<sub>1</sub>: OR 1.15, 95%CI 1.07-1.24, p 0.0002). Instead, if the FEV<sub>1</sub> fell higher  $\geq$  20%, the presence of dyspnea was related to the degree of bronchoconstriction ( $\Delta$ FEV<sub>1</sub>: OR 1.04, 95%CI 1.01-1.09, p 0.0187), females (OR 3.02, 95%CI 1.36-6.72, p 0.0067), younger subjects (OR 0.92, 95%CI 0.88-0.96, p 0.0007) and BMI (OR 1.12, 95%CI 1.01-1.23, p 0.023). The quality of dyspnea during the bronchoconstriction was similar in women and men; women showed a higher perception of dyspnea than men only when the FEV<sub>1</sub> fell more than 20% from baseline.

**Key words:** asthma, breathlessness, bronchoconstriction, bronchial hypereactivity, dyspnea, perception of airway narrowing

**Resumen** *Género y percepción de disnea: el rol de la variación del volumen espiratorio forzado en un segundo.* Durante la broncoconstricción las mujeres perciben más disnea que los hombres. Los objetivos del estudio fueron evaluar: 1) si la calidad de la disnea durante la broncoconstricción fue diferente en mujeres y hombres, 2) si la diferencia entre sexos en la percepción de disnea podría relacionarse al nivel de broncoconstricción. 457 sujetos (257 mujeres) inhalaban metacolina hasta un descenso del FEV<sub>1</sub>  $\geq$  20% o 32 mg/ml. La disnea fue evaluada mediante escala de Borg y una lista de expresiones de disnea. El Borg fue registrado en forma basal y con el máximo descenso del FEV<sub>1</sub>. La frecuencia de descriptores de disnea informados por mujeres y hombres fue similar. La disnea estuvo relacionada al grado de broncoconstricción ( $\Delta$ FEV<sub>1</sub>: OR 1.05, 95%CI 1.01-1.09, p 0.0095), sexo femenino (OR 2.90, 95%CI 1.33-6.33, p 0.0072), edad (OR 0.93, 95%CI 0.89-0.97, p 0.0013) e índice de masa corporal (IMC) (OR 1.11, 95%CI 1.01-1.23, p 0.023). Cuando el FEV<sub>1</sub> cayó menos del 20%, solo el  $\Delta$ FEV<sub>1</sub> se asoció con disnea ( $\Delta$ FEV<sub>1</sub>: OR 1.15, 95%CI 1.07-1.24, p 0.0002). En tanto que si el FEV<sub>1</sub> cayó  $\geq$  del 20%, la disnea estuvo relacionada al grado de broncoconstricción ( $\Delta$ FEV<sub>1</sub>: OR 1.04, 95%CI 1.01-1.09, p 0.0187), sexo femenino (OR 3.02, 95%CI 1.36-6.72, p 0.0067), edad (OR 0.92, 95%CI 0.88-0.96, p 0.0007) e IMC (OR 1.12, 95%CI 1.01-1.23, p 0.023). La calidad de la disnea durante la broncoconstricción fue similar en hombres y mujeres; las mujeres tuvieron mayor percepción de disnea que los hombres solo cuando el FEV<sub>1</sub> descendió más del 20%.

**Palabras clave:** asma, disnea, broncoconstricción, hiperreactividad bronquial, percepción de la broncoconstricción

Asthmatic patients vary greatly in the perception of their symptoms of bronchial obstruction<sup>1-4</sup>. Discrepancies in perception may be due to differences in the disease severity, in methods assessing the dyspnea, or in cul-

tural characteristics of the study population<sup>5</sup>. The influence of sex in the perception of dyspnea during induced bronchoconstriction has been evaluated in several reports that used explanatory multiple regression models<sup>6-10</sup>. After adjusting for potential confounders, most of the studies showed that women had a higher perception of breathlessness than men<sup>6-9</sup>. These observations are in accordance with some reports that found females used more rescue medications for asthma<sup>11</sup>, reported more symptoms and had poorer quality of life than men at the

Received: 9-III-2009

Accepted: 15-I-2010

**Dirección postal:** Carlos A. Nigro, Avda. Pedro Goyena 620 - 3° B - 1424 Buenos Aires, Argentina

Fax: (54-11) 4827-7000, interno 2722 e-mail: cnigro@intramed.net

same level of airflow obstruction<sup>12,13</sup>. Gender differences in airway behaviour and in the clinical manifestations of airway disease occur throughout the human life span and are related to biological as well as sociocultural factors<sup>14</sup>. The term dysanapsis has been used to describe this disproportionate but physiologically normal growth between the airways and the lung parenchyma. Mead et al<sup>15</sup> estimated that the airways of men were approximately 17% larger in diameter than the airways of women, and speculated that the adult sex difference in airway size develops relatively late in the growth phase. The relation RV/TLC, an indicator of hyperinflation is higher in females than males and increases with age<sup>16</sup>. Because these biological gender differences, we postulated that the perception of dyspnea reported during a bronchospasm would be different in women and men. To investigate this question, we studied the dyspnea in women and men in whom bronchoconstriction was induced by inhalation of methacholine.

## Materials and Methods

We consecutively studied all subjects who attended the pulmonary laboratory from January 2002 to January 2005 to undergo a methacholine challenge test due to clinical suspicion of bronchial asthma. No comprehensive clinical details about individual patients were obtained. A routine medication questionnaire disclosed that 280 had been prescribed inhaled steroids and/or inhaled  $\beta_2$ -agonists and 59 had been prescribed oral theophylline or leukotriene receptor antagonist for the relief of symptoms. The inclusion criteria were: 1) Baseline FEV<sub>1</sub>  $\geq$  60% of predicted value taken from Morris and associates<sup>17</sup>, 2) Age > 12 years and 3) Informed consent. Exclusions included: 1) Deterioration in respiratory symptoms requiring any alteration in the subject's usual medication within 3 wk prior to the study, 2) Medical contraindications to methacholine challenge testing (heart disease, hypertension, thyroid disease, urinary obstruction, pregnancy, or lactation) and 3) Absence of any previous experience of sensory testing. The total number of subjects initially evaluated was 519 out of whom only 457 fulfilled inclusion and exclusion criteria (257 women and 200 men). The Hospital Alemán's institutional review board approved the study protocol.

All subjects were asked to abstain from drinks containing caffeine and from oral theophylline and leukotriene receptor antagonist for 48 hours before the challenge, and from all inhaled medications for 24 hours prior to the methacholine test. Spirometry was measured by a flow sensing spirometer connected to a computer for data analysis (Med Graphics 1085DL-Medical Graphics Co, St Paul, MN, USA). Each patient underwent an abbreviated methacholine challenge test. Baseline FEV<sub>1</sub> was taken as the best of three technically satisfactory measurements performed immediately before the challenge. After baseline spirometry had been made sequential, concentrations of buffered methacholine chloride were administered at 5-min intervals. When the baseline spirometry showed airflow obstruction (FEV<sub>1</sub>/FVC < 0.75), the starting concentration of methacholine was 0.125 mg/ml. In all other instances, the initial concentration of methacholine was 0.5 mg/ml. We skipped one concentration of methacholine if the fall in FEV<sub>1</sub> respect to the baseline value was lower than 5%. Each dose of methacholine was inhaled by tidal breathing for 2 min using a mouthpiece with noseclips. Solutions were delivered in 3 ml aliquots via a nebulizer DeVilbiss 646 (DeVilbiss Co, Somerset, PA, USA) calibrated to deliver 0.13-0.16 ml/min. and driven by compressed air. Spirometry was measured 30 and 90 s after each dose, and values from the flow-volume loop with the highest post dose FEV<sub>1</sub> were used for analysis. The test was terminated when the FEV<sub>1</sub> decreased by  $\geq$  20% of the highest baseline value or when the greater dose of methacholine had been administered. Bronchial responsiveness, expressed as the concentration of methacholine producing a 20% fall in FEV<sub>1</sub> from the highest baseline FEV<sub>1</sub> (PC<sub>20</sub>) was calculated<sup>18</sup>.

Dyspnea was defined as the presence of one or more of the descriptors listed in Table 1. The list of terms for dyspnea in the Spanish language included in this study was compiled by reviewing the literature and consulting patients. The literal translation of most of the main descriptors previously published for the English language was included<sup>19-21</sup>. The 8-item list of dyspnea descriptors was given to the subjects by the investigator. Subjects were instructed to read the entire list of 8 phrases before making their choices. Patients were asked to choose one or more of the phrases that best described their "breathing discomfort" at that time. Each subject was aware of the option of choosing none of the phrases. Following this, subjects were instructed to grade the intensity of their breathlessness by assigning a numerical value using a modified Borg scale<sup>22</sup> and its end points were anchored so that 0 and 10 were used to indicate "no breathlessness" and "the most breathlessness that the subject had experienced, respectively. All subjects were asked to ignore other methacholine related

TABLE 1.— Descriptors of dyspnea in English/Spanish

My chest feels tight. My chest is constricted	Siento mi pecho cerrado o apretado
My breath does not go in all the way. Breathing in more difficult	Mi respiración no entra bien. Tengo dificultad para entrar el aire
My breathing requires more work. My breathing requires effort	Mi respiración requiere más esfuerzo. Mi respiración requiere esfuerzo
My breath does not go out all the way. Breathing out more difficult	Mi respiración no sale bien. Tengo dificultad para sacar el aire
My breathing is heavy	Mi respiración es pesada
I feel that I am smothering	Siento que me estoy asfixiando
I feel that I am suffocating	Siento que me estoy sofocando o agitando
Shortness of breath	Falta de aire

symptoms such as cough, salivation, flushing or irritation of the nose or throat. Borg scores were recorded immediately before the challenge test baseline and at the maximum decrease of FEV<sub>1</sub>.

Comparisons of predicted FEV<sub>1</sub>, forced vital capacity (FVC), FEV<sub>1</sub>/FVC and age were performed using unpaired Student's t test. Comparisons between or within groups for variables such as maximal Borg scores and the reduction in FEV<sub>1</sub> as a percentage of the baseline value ( $\Delta$ FEV<sub>1</sub>) were made using Mann-Whitney U- test. The frequency of symptoms reported by men and women during bronchoconstriction was compared using the Chi-Square test. All tests were performed two-sided, and a p value of < 0.05 was considered to be significant. Multiple logistic regression analysis was performed to determine the relationship between the Borg (depend variable 0 = no, 1 = yes) and the following independent variables: age, sex (1 = female, 0 = male), baseline predicted FEV<sub>1</sub>, baseline predicted FVC, relation FEV<sub>1</sub>/FVC, body mass index (BMI),  $\Delta$ FEV<sub>1</sub> and PC<sub>20</sub> (0 =  $\geq$  2 MG/ML, 1 = < 2 MG/ML). In order to evaluate if the gender difference in the perception of dyspnea was associated with the level of FEV<sub>1</sub>, we divided the subjects in two groups according to the  $\Delta$ FEV<sub>1</sub> ( $\Delta$ FEV<sub>1</sub> < 20% and  $\geq$  20%) and multiple logistic regression analysis was applied. In this case the PC<sub>20</sub> was not included in the model because it could not be calculated in  $\Delta$ FEV<sub>1</sub> < 20% group.

## Results

One hundred and seventy patients showed a fall in the baseline FEV<sub>1</sub> lower than 20% (37%) and two hundred and eighty seven (63%) had a decrease in baseline FEV<sub>1</sub> equal or higher than 20%. At the beginning of the methacholine challenge, no patients had dyspnea. The median change in the Borg score was 4 (25-75th percentile 0-6) and the median reduction in FEV<sub>1</sub> as a percentage of baseline value was 23% (25-75th percentile 15-33). Fifty patients (27 women) had baseline mild airway obstruction (FEV<sub>1</sub> between 60 to 80% of predicted and FEV<sub>1</sub>/FVC < 0.75). The baseline predicted FEV<sub>1</sub> was similar in women than men (mean FEV<sub>1</sub>: 70.4  $\pm$  6.1% vs. 72.5  $\pm$  5%, p 0.19). The female and male patients' characteristic and score Borg changes during methacholine challenges are shown in Table 2. The age and  $\Delta$ FEV<sub>1</sub> were lightly greater in women than men (43.2  $\pm$  17.7 vs. 37.2  $\pm$  16.8 years, p 0.0003; 23.6%, 25-75th percentile 16 - 35 vs. 20.5%, 25-75th percentile 13.4-32, p 0.04) and the BMI was higher

TABLE 2.— Female and male patient characteristic and score Borg changes during methacholine challenges

	Female	Male	p
Number	257	200	
Age (yrs) #	43.2 $\pm$ 17.7	37.2 $\pm$ 16.8	< 0.0003
BMI (Kg/m <sup>2</sup> ) #	24.2 $\pm$ 4.6	25.4 $\pm$ 4	< 0.002
FVC (% pred.) #	97.1 $\pm$ 12.5	94.7 $\pm$ 14.2	0.06
FEV <sub>1</sub> (% pred.) #	91.7 $\pm$ 13.5	89.5 $\pm$ 13.8	0.09
FEV <sub>1</sub> /FVC #	78.9 $\pm$ 7.6	77.3 $\pm$ 8.5	0.53
PC <sub>20</sub> Mch. (mg/ml)*	3.5 (1.6 – 5.8)	3.5 (2.2 – 6.2)	0.59
$\Delta$ FEV <sub>1</sub> (% of baseline)*	23.6 (16 – 35)	20.5 (13.4 – 32)	0.04
Maximal Borg*	5 (0 – 6)	4 (0 – 6)	0.18

Data are expressed as # the mean  $\pm$  SD or \* median (25% -75% percentiles).  $\Delta$ FEV<sub>1</sub> (% of baseline): reduction in FEV<sub>1</sub> as a percentage of the baseline value.

TABLE 3.— Quality of dyspnea during methacholine challenges

Descriptors of dyspnea	Female (%)	Male (%)	p
My chest feels tight / My chest is constricted	88.7	85.5	NS
My breath does not go in all the way / Breathing in more difficult	86.4	83.9	NS
My breathing requires more work / My breathing requires effort	90.9	83.9	NS
My breath does not go out all the way / Breathing out more difficult	74.6	75	NS
My breathing is heavy	76.3	82.2	NS
I feel that I am smothering	84.2	82.2	NS
I feel that I am suffocating	76.8	77.4	NS
Breathless	82.5	79	NS

in men than women ( $25.4 \pm 4$  vs.  $24.2 \pm 4.6$ ,  $p < 0.002$ ). The maximal Borg score was similar in females and males (5, 25-75th percentile 0-6 vs. 4, 25-75th percentile 0-6,  $p 0.18$ ). At maximal bronchoconstriction, 314 out of 457 subjects (69%) reported the presence of one or more descriptors of dyspnea whereas 143 (31%) reported none (71 females and 72 males). The frequency of descriptors of dyspnea selected by women and men during the methacholine challenge was similar (Table 3). After adjusting for possible confounding variables all patients showed that dyspnea was related to the level of decline in  $FEV_1$  ( $\Delta FEV_1$ : OR 1.05, 95%CI 1.01-1.09,  $p 0.0095$ ), females (OR 2.90, 95%CI 1.33-6.33,  $p 0.0072$ ), younger subjects (OR 0.93, 95%CI 0.89-0.97,  $p 0.0013$ ) and BMI (OR 1.11, 95%CI 1.01-1.23,  $p 0.023$ ) (Table 4). Similarly, after excluding patients with airflow obstruction, dyspnea was

associated with the same variables that the entire population ( $\Delta FEV_1$ : OR 1.05, 95%CI 1.01-1.09,  $p 0.0095$ ; females: OR 2.1, 95%CI 1.16-3.9,  $p 0.015$ ; age: OR 0.95, 95%CI 0.92-0.98,  $p 0.0023$ , BMI: OR 1.09, 95%CI 1.01-1.17,  $p 0.019$ ). Table 5 shows the characteristics of groups according to the  $\Delta FEV_1$ . When bronchoconstriction was mild ( $\Delta FEV_1 < 20\%$ ) only the  $\Delta FEV_1$  was significantly associated with dyspnea ( $\Delta FEV_1$ : OR 1.15, 95%CI 1.07-1.24,  $p 0.0002$ ) (Table 6). On the other hand, when bronchoconstriction was more severe ( $\Delta FEV_1 \geq 20\%$ ), the presence of dyspnea was related to the degree of bronchoconstriction ( $\Delta FEV_1$ : OR 1.04, 95%CI 1.01-1.09,  $p 0.0187$ ), females (OR 3.02, 95%CI 1.36-6.72,  $p 0.0067$ ), younger subjects (OR 0.92, 95%CI 0.88-0.96,  $p 0.0007$ ) and BMI (OR 1.12, 95%CI 1.01-1.23,  $p 0.023$ ) (Table 7).

TABLE 4.— Multiple logistic regression analysis in all patients relating the Borg to the  $\Delta FEV_1$ , age, baseline spirometry, BMI, sex and  $PC_{20}$

Variable	Coefficient	Std Err	OR	95%CI	p
$\Delta FEV_1$ (% of baseline)	0.051	0.019	1.05	1.01 - 1.09	0.0095
Age	-0.069	0.021	0.93	0.89 - 0.97	0.0013
$FEV_1/FVC$	-0.181	0.136	0.83	0.64 - 1.09	0.1816
$FEV_1$ (% pred.)	0.127	0.123	1.13	0.89 - 1.45	0.3021
FVC (% pred.)	-0.111	0.118	0.89	0.70 - 1.13	0.3451
BMI	0.109	0.048	1.11	1.01 - 1.23	0.0230
Sex	1.067	0.397	2.90	1.33 - 6.33	0.0072
$PC_{20}$	-0.036	0.358	0.96	0.478 - 1.95	0.9196

OR: odds ratio. 95%CI: 95% confidence interval.  $\Delta FEV_1$  (% of baseline): reduction in  $FEV_1$  as a percentage of the baseline value; Std Err: Standard Error.

TABLE 5.— Characteristics of the analyzed subgroups

	$\Delta FEV_1 < 20\%$	$\Delta FEV_1 \geq 20\%$	p
Number	170 (37.2%)	287 (62.8%)	< 0.0001
Age (yrs) <sup>#</sup>	44.5 ± 17	38.3 ± 17.5	< 0.0002
Female/male	87/83	170/117	
BMI (Kg/m <sup>2</sup> ) <sup>#</sup>	25.1 ± 4.2	24.5 ± 4.5	0.16
FVC (% pred.) <sup>#</sup>	97.3 ± 14.5	95.4 ± 12.5	0.14
$FEV_1$ (% pred.) <sup>#</sup>	95 ± 13.8	88.2 ± 13	< 0.0001
$FEV_1/FVC$ <sup>#</sup>	80.8 ± 7.2	77.5 ± 8.3	< 0.0001
$\Delta FEV_1$ (% of baseline)*	12.3 (7.9 - 15.7)	29.5 (23.6 - 41.3)	< 0.0001
Maximal Borg*	0 (0 - 5)	5 (3 - 7)	< 0.0001
Borg = 0	96 (56%)	47 (16%)	< 0.0001

Data are expressed as # the mean ± SD or \* median (25% -75% percentiles).  $\Delta FEV_1$  (% of baseline): reduction in  $FEV_1$  as a percentage of the baseline value.

TABLE 6.— Multiple logistic regression analysis in patients with  $\Delta FEV_1 < 20$  relating the Borg to the  $\Delta FEV_1$ , age, baseline spirometry, BMI and sex

Variable	Coefficient	Std Err	OR	95%CI	p
$\Delta FEV_1$ (% of baseline)	0.143	0.038	1.15	1.07 - 1.24	0.0002
Age	-0.020	0.019	0.97	0.94 - 1.01	0.2995
$FEV_1/FVC$	0.135	0.125	1.14	0.89 - 1.46	0.2784
$FEV_1$ (% pred.)	-0.169	0.105	0.84	0.68 - 1.03	0.1088
FVC (% pred.)	0.139	0.100	1.14	0.94 - 1.40	0.1667
BMI	0.043	0.047	1.04	0.95 - 1.14	0.3622
Sex	0.447	0.402	1.56	0.71 - 3.44	0.2657

OR: odds ratio. 95%CI: 95% confidence interval.  $\Delta FEV_1$  (% of baseline): reduction in  $FEV_1$  as a percentage of the baseline value.

TABLE 7.— Multiple logistic regression analysis in patients with  $\Delta FEV_1 \geq 20$  relating the Borg to the  $\Delta FEV_1$ , age, baseline spirometry, BMI and sex

Variable	Coefficient	Std Err	OR	95%CI	p
$\Delta FEV_1$ (% of baseline)	0.047	0.020	1.04	1.01 - 1.09	0.0187
Age	-0.075	0.022	0.92	0.88 - 0.96	0.0007
$FEV_1/FVC$	-0.185	0.139	0.83	0.63 - 1.09	0.1835
$FEV_1$ (% pred.)	0.133	0.126	1.14	0.89 - 1.46	0.2917
FVC (% pred.)	-0.112	0.121	0.89	0.70 - 1.12	0.3554
BMI	0.114	0.049	1.12	1.01- 1.23	0.0203
Sex	1.106	0.407	3.02	1.35 - 6.72	0.0067

OR: odds ratio. 95%CI: 95% confidence interval.  $\Delta FEV_1$  (% of baseline): reduction in  $FEV_1$  as a percentage of the baseline value.

## Discussion

The main findings of study were that 1) acute bronchoconstriction produce the same quality of dyspnea in women and men, and 2) women had more probability to report dyspnea than men when the  $FEV_1$  descended more than 20%. Although the gender differences previously published in the airways caliber and lung size, we could not demonstrate that the prevalence of the different descriptors of dyspnea reported at the maximum bronchoconstriction was different in women and men (Table 4). On the other hand, as the  $FEV_1$  decreased less than 20% (median 12%), the perception of dyspnea was similar in both genders. Instead, when the  $FEV_1$  reduced  $\geq 20\%$  (median 29%) from baseline, women reported more frequently dyspnea than men (Tables 6 and 7). The association between gender and perception of dyspnea could be related to the close relationship between the sensation of breathlessness and respiratory effort. Loughheed et al<sup>23</sup> showed that the inspiratory effort quantified by tidal change of oesophageal pressure as a per-

centage of maximal inspiratory pressure ( $\Delta Pes / \% P_{I\max}$ ) progressively increased during induced bronchoconstriction by  $17 \pm 3$  cm  $H_2O$  or  $31 \pm 6$  % of maximal inspiratory pressure ( $P_{I\max}$ ). Likewise, they observed that  $\Delta Pes / \% P_{I\max}$  was the strongest single correlate of breathlessness ( $r = 0.84$ ,  $p < 0.001$ ). Although we did not measure respiratory effort, we speculate that at the same level of bronchoconstriction, women possibly perform more inspiratory effort ( $\Delta Pes / \% P_{I\max}$ ) than men because their  $P_{I\max}$  is about 30% lower than in males<sup>24</sup>. Thus, women would have more probability to perceive the sensation of breathlessness than men. Possibly, at low levels of bronchoconstriction, the inspiratory effort in both genders is not enough to stimulate respiratory tract receptors and provoke an increase in the central motor command output with the consequent sense of breathlessness<sup>24, 25</sup>. As  $FEV_1$  falls more and the mechanical load on the system increases, women would have more probabilities to perceive dyspnea because their  $Pes/P_{I\max}$  (i.e., an estimation of central motor command output) is higher than men's at the same level of bronchoconstriction. Weiner et al<sup>26</sup>

studied the influence of gender and inspiratory muscle training on the perception of dyspnea (POD) in patients with mild asthma. For the same level of predicted FEV<sub>1</sub>, the Borg score sum and the mean daily  $\beta_2$ -agonist consumption in women were significantly higher than in men (Borg: 13.1 vs. 10.1,  $p < 0.01$ ;  $\beta_2$ -agonist consumption: 3.2 vs. 2,  $p < 0.05$ ). Besides, the increase in the PImax after inspiratory muscle training in asthmatic women was associated with a statistically significant decrease in their dyspnea perception to a similar level as in male subjects.

The identification of factors that influence the perception of bronchoconstriction is clinically important. Patients with low perception of dyspnea are at an increased risk of future hospitalization, a near-fatal asthma attack, or even death from an asthma attack<sup>27</sup>. We have showed that men have a lower perception of bronchoconstriction than women at higher levels of bronchoconstriction. Therefore, we could hypothesize that the male gender is a risk factor that may potentially increase morbidity and mortality by asthma. Several studies are in line with this hypothesis. Desideri et al<sup>28</sup> and Romano et al<sup>29</sup> showed that death rates for asthma were significantly higher in males than females. Campbell et al<sup>30</sup> showed that in near fatal asthma cases, patients tended to be younger, were more likely to be males, and less likely to have concurrent medical condition. Similarly, in comparison with those admitted with acute asthma, patients with severe life threatening asthma were more likely to be men<sup>31</sup>. However, other publications have showed the predominance of women in severe episodes or mortality by asthma<sup>32-37</sup>. Finally, in order to avoid a potential dangerous lack of perception in the male group of asthmatic patients, education programmes which should include self monitoring of peak expiratory flow, regular medical review and written action plans could reduce hospitalizations, emergency room visits or unscheduled doctor visits and could improve quality of life<sup>38, 39</sup>.

This study had several limitations: 1) The main predictive variable of breathlessness during a challenge test is the inspiratory capacity, which represents the level of hyperinflation. Since the  $\Delta$ FEV<sub>1</sub> was similar in women and men and there is a close relationship between the percentage of fall FEV<sub>1</sub> and inspiratory capacity<sup>23</sup> then it is probable that the degree of hyperinflation in both groups had not been substantially different. 2) We did not measure oxygen saturation (SO<sub>2</sub>), end tidal CO<sub>2</sub> (ETCO<sub>2</sub>) and breathing pattern during the bronchoconstriction with methacholine. These parameters could have modified the perception of breathlessness in women and men during the challenge test. Despite this, these variables do not change significantly during bronchoconstriction induced by methacholine<sup>23</sup>. 3) The methacholine challenge has its limitations as it does not reflect the real life situation of episodes of spontaneous bronchoconstriction. However, several publications have showed that the perception of

spontaneously bronchoconstriction is higher in women than men<sup>11-13, 40</sup>. 4) We did not know the smoking history and the proportion of patients with COPD in our sample study. It is probable that we have included subjects with COPD in our patient population. However, we think this has not influenced our results. In fact, Ekici et al<sup>7</sup> demonstrated that men with asthma, chronic bronchitis and bronchiectasis showed a lower perception of breathlessness than women. On the other hand, Brand et al<sup>9</sup> evaluated the perception of airway obstruction during histamine-induced bronchoconstriction in a heterogeneous population that included patients with and without smoking history and asthmatic subjects. The relation of possible confounding variables to an increase in Borg score was assessed in a multiple logistic regression. An increase in Borg score after histamine challenge was related to younger age, level of bronchial hyperreactivity, positive skin test and female sex. Similarly, de Torres et al<sup>41</sup> compared gender differences in the clinical expression of Chronic Obstructive Pulmonary Disease (COPD) patients. Even though women had the same FEV<sub>1</sub>, better oxygenation, better PaCO<sub>2</sub>, and fewer comorbidities than men, they had a higher degree of dyspnea (Modified Medical Research Council scale  $> 2$ , 28% vs. 6%,  $p 0.05$ ). Finally, we used a list of sentences for dyspnea that were a literal translation of most of the main descriptors published for the English language. It could have introduced a bias that modifies the perception of dyspnea. However, in the Spanish language<sup>42</sup>, most of the sentences describing breathlessness were the literal translation of most of the main dyspnea descriptors used in the English language. Besides, the reproducibility of Spanish and English dyspnea descriptors in patients with chronic lung disease was similar<sup>20, 21, 42</sup>.

In conclusion, the quality of dyspnea in bronchoconstriction was similar in women and men, but the likelihood to perceive dyspnea with moderate to severe airway obstruction was higher in female than male. At lesser degrees of bronchoconstriction, both males and females had a similar perception of breathlessness.

**Conflicts of interests:** We declare there were no conflicts of interest related to this investigation.

## References

1. Pfeiffer C, Marsac J, Lockart A. Chronobiological study of the relationship between dyspnea and airway obstruction in symptomatic asthmatic subjects. *Clin Sci* 1989; 77: 237-44.
2. Orehek J, Beaupre A, Badier M, et al. Perception of airway tone by asthmatic patients. *Bull Eur Physiopathol Respir* 1982; 18: 601-7.
3. Rubinfeld AR, Pain MCF. Perception of asthma. *Lancet* 1976; 24: 882-4.
4. Burdon JGW, Juniper EF, Killian KJ, et al. The perception of breathlessness in asthma. *Am Rev Respir Dis* 1982; 126: 825-8.

5. Chetta A, Gerra G, Foresi A, et al. Personality profiles and breathlessness perception in outpatients with different grading of asthma. *Am J Respir Crit Care Med* 1998; 157: 116-22.
6. Killian KJ, Watson R, Otis J, et al. Symptom perception during acute bronchoconstriction. *Am J Respir Crit Care Med* 2000; 162: 490-6.
7. Ekici A, Yilmaz S, Ekici M, et al. Perception of bronchoconstriction in obstructive pulmonary disease (disease-specific dyspnea). *Clin Sci* 2003; 105: 181-5.
8. Devereux G, Hendrick DJ, Stenton SC. Perception of respiratory symptoms after metacholine-induced bronchoconstriction in a general population. *Eur Respir J* 1998; 12: 1089-93.
9. Brand PL, Rijcken B, Schouten JP, Postma DS. Perception of airway obstruction in a random population sample. Relationship to airway hyperresponsiveness in the absence of respiratory symptoms. *Am Rev Respir Dis* 1992; 146: 396-401.
10. Bijl-Hofland ID, Cloosterman SG, Folgering HT, et al. Relation of the perception of airways obstruction to the severity of asthma. *Thorax* 1999; 54: 15-9.
11. Redline S, Gold D. Challenges in interpreting gender differences in asthma. *Am J Respir Crit Care Med* 1994; 150: 1219-21.
12. Osborne ML, Vollmer WM, Linton KL, Buist AS. Characteristics of patients with asthma within a large HMO. *Am J Respir Crit Care Med* 1998; 157: 123-8.
13. Trawick DR, Holm C, Wirth J. Influence of gender on rates of hospitalization, hospital course, and hypercapnea in high risk patients admitted for asthma. *Chest* 2001; 119: 115-9.
14. Becklake MR, Kauffmann F. Gender differences in airway behaviour over the human life span. *Thorax* 1999; 54: 1119-38.
15. Mead J. Dyanapsis in normal lungs assessed by the relationship between maximal flow, static recoil, and vital capacity. *Am Rev Respir Dis* 1980; 121: 339-42.
16. Hibbert H, Lannigan A, Raven J, et al. Gender differences in lung growth. *Pediatr Pulmonol* 1995; 19: 129-34.
17. Morris JF, Koski WA, Johnson LC. Spirometric standards for healthy nonsmoking adults. *Am Rev Respir Dis* 1971; 103: 57-67.
18. Crapo RO, Casaburi R, Coates AL, et al. Guidelines for methacholine and exercise challenge testing-1999. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. *Am J Respir Crit Care Med* 2000; 161: 309-29.
19. Simon PM, Schwartzstein RM, Weiss JW, et al. Distinguishable types of dyspnea in patients with shortness of breath. *Am Rev Respir Dis* 1990; 142: 1009-14.
20. Mahler DA, Harver A, Lentine T, et al. Descriptors of breathlessness in cardiorespiratory diseases. *Am J Respir Crit Care Med* 1996; 154: 1357-63.
21. Elliott MW, Adams L, Cockcroft A, et al. The language of breathlessness. Use of verbal descriptors by patients with cardiopulmonary disease. *Am Rev Respir Dis* 1991; 144: 826-32.
22. el-Manshawi A, Killian KJ, Summers E, Jones NL. Breathlessness during exercise with and without resistive load. *J Appl Physiol* 1986; 61: 896-905.
23. Loughheed MD, Lam M, Forkert L, et al. Breathlessness during acute bronchoconstriction in asthma. *Am Rev Respir Dis* 1993; 148: 1452-9.
24. Vincken W, Ghezze H, Cosio MG. Maximal static respiratory pressures in adults: normal values and their relationship to determinants of respiratory function. *Bull Eur Physiopathol Respir* 1987; 23: 435-9.
25. Dyspnea. Mechanisms, assessment, and management: a consensus statement. American Thoracic Society. *Am J Respir Crit Care Med* 1999; 159: 321-40.
26. Weiner P, Magadle R, Massarwa F, et al. Influence of gender and inspiratory muscle training on the perception of dyspnea in patients with asthma. *Chest* 2002; 122: 197-201.
27. Magadle R, Berar-Yanay N, Weiner P. The risk of hospitalization and near-fatal and fatal asthma in relation to the perception of dyspnea. *Chest* 2002; 121: 329-33.
28. Desideri M, Viegi G, Carrozzi L, et al. Mortality rates for respiratory disorders in Italy (1979-1990). *Monaldi Arch Chest Dis* 1997; 52: 212-6.
29. Romano F, Recchia G, Staniscia T, et al. Rise and fall of asthma-related mortality in Italy and sales of beta2-agonists, 1980-1994. *Eur J Epidemiol* 2000; 16: 783-7.
30. Campbell DA, McLennan G, Coates JR, et al. A comparison of asthma deaths and near-fatal asthma attacks in South Australia. *Eur Respir J* 1994; 7: 490-7.
31. Kolbe J, Fergusson W, Vamos M, Garrett J. Case-control study of severe life threatening asthma (SLTA) in adults: demographics, health care, and management of the acute attack. *Thorax* 2000; 55: 1007-15.
32. Richards GN, Kolbe J, Fenwick J, Rea HH. Demographic characteristics of patients with severe life threatening asthma: comparison with asthma deaths. *Thorax* 1993; 48: 1105-9.
33. Wareham NJ, Harrison BD, Jenkins PF, et al. A district confidential enquiry into deaths due to asthma. *Thorax* 1993; 48: 1117-20.
34. Sears MR, Rea HH, Beaglehole R, et al. Asthma mortality in New Zealand: a two year national study. *N Z Med J* 1985; 98: 271-5.
35. Ormerod LP, Stableforth DE. Asthma mortality in Birmingham 1975-7: 53 deaths. *Br Med J* 1980; 280: 687-90.
36. Cochran GM, Clark JH. A survey of asthma mortality in patients between ages 35 and 64 in the Greater London hospitals in 1971. *Thorax* 1975; 30: 300-5.
37. Westerman DE, Benatar SR, Potgieter PD, Ferguson AD. Identification of the high-risk asthmatic patient. Experience with 39 patients undergoing ventilation for status asthmaticus. *Am J Med* 1979; 66: 565-72.
38. Gibson PG, Coughlan J, Wilson AJ, et al. Self-management education and regular practitioner review for adults with asthma. *The Cochrane Library* 1998.
39. Powell H, Gibson PG. Options for self-management education for adults with asthma. *Cochrane Database Sys Rev* 2003.
40. Skobeloff EM, Spivey WII, St Clair SS, Schoffstall JM. The influence of age and sex on asthma admissions. *JAMA* 1992; 268: 3437-40.
41. de Torres JP, Casanova C, Hernández C, et al. Gender and COPD in patients attending a pulmonary clinic. *Chest* 2005; 128: 2012-26.
42. Vázquez-García JC, Balcázar-Cruz CA, Cervantes-Méndez G, et al. Descriptors of breathlessness in Mexican Spanish. *Arch Bronconeumol* 2006; 42: 211-7.